Topicals in Focus: Pediatric Atopic Dermatitis Insights at Elevate-Derm Summer

Shanna Miranti, MPAS, PA-C, describes her clinical approach for managing moderate to severe pediatric atopic dermatitis and how she selects between the 3 available non-steroidal topicals.

In a discussion on pediatric AD management, Shanna Miranti, MPAS, PA-C, emphasized the enduring role of topical treatments for residual itch and flares, and highlighted the importance of rapid-acting agents such as ruxolitinib cream.

Shanna Miranti, MPAS, PA-C, discusses the impact of sleep loss in pediatric atopic dermatitis and the potential of emerging therapies in young patients, such as ruxolitinib cream, to improve outcomes.

Tina Bhutani, MD, MAS, discusses innovative pediatric atopic dermatitis treatments, including ruxolitinib cream, emphasizing collaborative decision-making for effective management.

Tina Bhutani, MD, MAS, highlights emerging topical treatments for pediatric atopic dermatitis, emphasizing improved adherence in younger children, the potential impact of ruxolitinib FDA approval for ages 2 and up, and the promise of ongoing trials in infants under 2 years.

Walter Liszewski, MD, discusses the personalized and evolving treatment landscape for moderate to severe AD, emphasizing a tailored approach using new biologics and non-steroidal topicals to meet individual patient needs and expectations.

At the Elevate-Derm Summer 2025 meeting, Walter Liszewksi, MD, discussed how new topical therapies, particularly JAK inhibitors, are transforming AD care with rapid itch relief, effectiveness in complex cases, and patient-friendly formulations for sensitive areas.

Walter Liszewski, MD, shares expert strategies for managing body surface area limitations in AD treatment using non-steroidal topicals, and explored key unmet needs in the current therapeutic landscape.